Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icaritin Soft Capsules Combined With mFOLFOX-HAIC in HCC With High-risk Recurrence Factors
NCT07337460Phase 2Recruiting
- Sponsor
- Subei People's Hospital
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Icaritin in hepatocellular carcinoma (HCC), sponsored by Subei People's Hospital. Primary endpoint: Recurrence-Free Survival at 2 years. Started Nov 2025; status: recruiting.
02
Drugs
Icaritin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07337460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07337460.